<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of findings in SCSTs&lt;sup&gt;[1-3]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of findings in SCSTs<sup>[1-3]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Comparison of findings in SCSTs<sup>[1-3]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Tumor</td> <td class="subtitle1">Age at presentation</td> <td class="subtitle1">Characteristic features of the ovarian mass</td> <td class="subtitle1">Hormonal effects*</td> <td class="subtitle1">Other potential tumor markers</td> <td class="subtitle1">Behavior</td> </tr> <tr class="divider_bottom"> <td>Fibroma</td> <td> <ul> <li>Usually postmenopausal women (average age 48) </li> </ul> </td> <td> <ul> <li>Gross: Firm white tumor. </li> <li>U/S: Usually unilateral hyper- or hypoechoic mass, which may be calcified and/or exhibit cystic degeneration. Ascites is present in 10 to 15% of cases and hydrothorax in 1%, especially with larger lesions. </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>CA 125 </li> </ul> </td> <td> <ul> <li>Benign </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Thecoma</td> <td> <ul> <li>Postmenopausal women </li> </ul> </td> <td> <ul> <li>Gross: Yellow, can be very large (40 cm). </li> <li>U/S: Unilateral and solid. Ascites is rare. </li> </ul> </td> <td> <ul> <li>Signs/symptoms of excess estrogen. Endometrial hyperplasia and carcinoma are present in approximately 15 and 20 to 25% of cases, respectively. </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Benign </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Fibrosarcoma</td> <td> <ul> <li>Postmenopausal women </li> </ul> </td> <td> <ul> <li>Gross: Lobulated. </li> <li>U/S: Unilateral, solid but may have areas of hemorrhage and necrosis. </li> </ul> </td> <td> <ul> <li>None </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Malignant </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Luteinized thecoma associated with sclerosing peritonitis</td> <td> <ul> <li>Broad age range </li> </ul> </td> <td> <ul> <li>Gross: Surface may be smooth, polypoid, lobulated, or cerebriform. </li> <li>U/S: Bilateral and solid. Massive ascites is common. </li> </ul> </td> <td> <ul> <li>Hormonal manifestations are usually absent. Rare cases associated with estrogen or androgen production. </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Benign. However, it can be associated with significant morbidity and occasional death due to severe adhesive disease and bowel obstruction. </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Granulosa cell tumor</td> <td> <ul> <li>Adult subtype occurs most commonly in middle-aged and older women (median age 50 to 54 years) and comprises 95% of these neoplasms </li> <li>Juvenile subtype typically develops before puberty, and comprises 5% of all granulosa cell tumors </li> </ul> </td> <td> <ul> <li>Gross: Appearance is variable; usually large (mean diameter 12 cm but may be as large as 30 cm), tan or yellow, and either soft or firm. </li> <li>U/S: Usually unilateral, echogenic, septated cystic, or solid mass. May resemble a mucinous cystadenoma or be filled with serous fluid or clotted blood. Ascites may be present. Torsion, intraneoplasmal hemorrhage, or tumor rupture with hemoperitoneum may be seen. </li> </ul> </td> <td> <ul> <li>Signs/symptoms of excess estrogen in over one-half of patients. Endometrial hyperplasia/intraepithelial neoplasia in 25 to 50% and endometrial carcinoma in 5 to 10%. The endometrial adenocarcinomas are usually early stage and well differentiated. </li> <li>Virilization is possible, but rare. </li> </ul> </td> <td> <ul> <li>Inhibin<sup>¶</sup> </li> <li>AMH<sup>Δ</sup> </li> <li>CA 125 </li> </ul> </td> <td> <ul> <li>Malignant </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Sertoli-Leydig cell tumor</td> <td> <ul> <li>Usually in the second and third decades of life </li> <li>Approximately 75% occur in women under age 40 years (mean age at diagnosis is 25), but they occur in all age groups </li> </ul> </td> <td> <ul> <li>Gross: Yellow and lobulated, with a smooth external surface. Well-differentiated neoplasms with retiform components are often soft and spongy, while poorly differentiated subtypes may have areas of hemorrhage and necrosis. </li> <li>U/S: Often large (average 16 cm in maximal diameter but may be &gt;20 cm). Most are unilateral and solid but may contain areas of closely packed small cysts. </li> </ul> </td> <td> <ul> <li>At least one-third of patients have virilization. Less than one-third of patients have signs/symptoms of excess estrogen. </li> </ul> </td> <td> <ul> <li>AFP<sup>◊</sup> </li> <li>Inhibin¶ </li> <li>CA 125 (rare) </li> </ul> </td> <td> <ul> <li>Benign or malignant </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Sex cord tumor with annular tubules (sporadic)</td> <td> <ul> <li>Average age 36 </li> </ul> </td> <td> <ul> <li>Gross: Often large. </li> <li>U/S: Unilateral, uncalcified. </li> </ul> </td> <td> <ul> <li>Almost all patients have signs/symptoms of excess estrogen. </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Benign or malignant </li> </ul> </td> </tr> <tr class="divider_bottom"> <td>Sex cord tumor with annular tubules (associated with Peutz-Jeghers syndrome)</td> <td> <ul> <li>Average age 27 (ie, younger than sporadic SCTAT) </li> </ul> </td> <td> <ul> <li>Gross: Usually small (&lt;3 cm). </li> <li>U/S: Bilateral, multifocal, calcified. </li> </ul> </td> <td> <ul> <li>Almost all patients have signs/symptoms of excess estrogen. </li> </ul> </td> <td> <ul> <li>N/A </li> </ul> </td> <td> <ul> <li>Usually benign </li> </ul> </td> </tr> <tr> <td>Sertoli cell tumor</td> <td> <ul> <li>Usually women of reproductive age, but may occur in children as young as age 2 and postmenopausal women </li> </ul> </td> <td> <ul> <li>Gross: Yellow to brown. </li> <li>U/S: Usually unilateral, solid, but may have several cystic areas. </li> </ul> </td> <td> <ul> <li>Approximately one-half produce functional hormones. Most commonly signs/symptoms of excess estrogen, but virilization can occur. Rarely both estrogens and androgens are produced. </li> </ul> </td> <td> <ul> <li>Renin (rare) </li> </ul> </td> <td> <ul> <li>Benign or malignant </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">SCST: sex cord-stromal tumor; U/S: ultrasound; CA 125: cancer antigen 125; N/A: not applicable; AMH: anti-müllerian hormone; SCTAT: sex cord tumors with annular tubules; AFP: alpha-fetoprotein.<br/>* Signs/symptoms of excess estrogen: abnormal uterine bleeding, menorrhagia, postmenopausal bleeding, breast tenderness, and precocious puberty in children. Signs/symptoms of excess androgen (virilization): oligomenorrhea, amenorrhea, breast atrophy, hirsutism, deepening voice, male pattern baldness, acne, and clitoral enlargement.<br/>¶ Inhibin usually becomes undetectable after menopause, unless produced by certain ovarian tumors, mostly mucinous epithelial ovarian carcinomas and granulosa cell tumors. Inhibin exists as two different isoforms, inhibin A and inhibin B, consisting of alpha and beta subunits. The alpha subunit is the same for both isoforms, while the beta subunits differ. In general, both inhibin A and inhibin B should be ordered, if possible.  The free alpha subunit can also be measured.<br/>Δ Anti-müllerian hormone (AMH, also known as müllerian inhibiting substance [MIS]) is produced by granulosa cells in the developing follicles. AMH is typically undetectable in postmenopausal women. An elevated AMH level appears to be highly specific for ovarian granulosa cell tumors.<br/><font class="lozenge">◊</font> AFP is often elevated (range from 4 to 14,000 ng/mL). However, it should be noted that the more common ovarian tumors that classically produce AFP are yolk sac tumors and embryonal carcinomas.</div><div class="graphic_reference">References:

	<ol>
<li>Al-Hussaini M, Al-Othman Y, Hijazi E, McCluggage WG. A Report of Ovarian Sertoli-Leydig Cell Tumors With Heterologous Intestinal-type Glands and Alpha Fetoprotein Elevation and Review of the Literature. Int J Gynecol Pathol 2018; 37:275.</li>
<li>Lim D, Oliva E. Ovarian sex cord-stromal tumours: an update in recent molecular advances. Pathology 2018; 50:178.</li>
<li>Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases. Am J Surg Pathol 1985; 9:543.</li>
</ol></div><div id="graphicVersion">Graphic 126482 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
